Free Trial
NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Avenue Therapeutics logo
$0.34 +0.08 (+31.80%)
As of 11:23 AM Eastern

About Avenue Therapeutics Stock (NASDAQ:ATXI)

Key Stats

Today's Range
$0.34
$0.34
50-Day Range
$0.18
$0.35
52-Week Range
$0.17
$3.93
Volume
357 shs
Average Volume
130,325 shs
Market Capitalization
$1.08 million
P/E Ratio
0.02
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avenue Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

ATXI MarketRank™: 

Avenue Therapeutics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Avenue Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avenue Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avenue Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.38.

  • Price to Book Value per Share Ratio

    Avenue Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avenue Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.55% of the float of Avenue Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 7.55%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Avenue Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Avenue Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.55% of the float of Avenue Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 7.55%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Avenue Therapeutics has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Avenue Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for ATXI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

  • Read more about Avenue Therapeutics' insider trading history.
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
Hoffmanns purchase building for boutique on Fifth Avenue South in Naples
See More Headlines

ATXI Stock Analysis - Frequently Asked Questions

Avenue Therapeutics' stock was trading at $2.00 on January 1st, 2025. Since then, ATXI stock has decreased by 83.0% and is now trading at $0.3399.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings results on Friday, August, 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $5.38.

Avenue Therapeutics's stock reverse split before market open on Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/09/2024
Today
7/03/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATXI
Fax
N/A
Employees
4
Year Founded
2015

Profitability

Trailing P/E Ratio
0.02
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.38 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.92 per share
Price / Book
0.18

Miscellaneous

Free Float
2,017,000
Market Cap
$1.08 million
Optionable
Not Optionable
Beta
-0.09

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ATXI) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners